#None #Dublin #Therapeutics #Acthar Gel #Keenova

Keenova Therapeutics' Strong Financial Performance in Q1 2026

Keenova Therapeutics plc, a prominent player in the therapeutic realm, has recently unveiled its financial performance for the first quarter of 2026. The company is notably recognized for its innovative products aimed at addressing rare and complex health issues. The quarter ending March 31, 2026, showcased remarkable growth and reaffirmed an optimistic outlook for the remainder of the year.

Financial Highlights

The latest report highlights some compelling figures:

• - Net Sales: Keenova reported net sales from continuing operations of $468 million, representing a $261 million increase compared to the same quarter in 2025.
• - Acthar Gel Sales: The sales for Acthar Gel reached $170 million, marking an impressive 47% growth from the previous year. This robust demand illustrates the expanding market share and acceptance of the product.
• - XIAFLEX Sales: The product XIAFLEX generated sales of $134 million, further contributing to the company's impressive revenue trajectory.
• - Adjusted EBITDA: The company reported an adjusted EBITDA of $174 million, reflecting the successful implementation of its operational strategies.

CEO Siggi Olafsson expressed enthusiasm regarding these results, emphasizing that the strong demand for Acthar Gel and XIAFLEX has reinforced the company's strategic direction. He pointed out that the growth in Acthar Gel sales is bolstered by increased patient access and expanded advertising efforts.

Strategic Developments and Future Outlook

Keenova is progressing with its synergy plan, reporting $23 million in synergies in Q1 2026. The company has set its sights on realizing $100 million in pre-tax merger synergies by the end of the year, with an ultimate goal of $150 million annually by the third anniversary of the merger with Endo LP.

Olafsson also highlighted upcoming developments with the XIAFLEX pipeline. The company is gearing up for top-line results from its Phase 3 study on Plantar Fibromatosis, which are expected in July 2026, with regulatory submissions targeted for Q4 of the same year. Additionally, a significant awareness campaign is in progress for Dupuytren's contracture, which is anticipated to drive demand further.

Keenova has confidently reaffirmed its 2026 financial guidance:

• - Projected net sales in the range of $1.94 billion to $2.00 billion.
• - Anticipated adjusted EBITDA ranging from $730 million to $760 million.

These projections exclude any impact from potential acquisitions or divestitures.

Ongoing Challenges and Considerations

Despite these successes, the company also faces challenges. The loss from continuing operations amounted to $114 million, an increase from $75 million in the previous year's quarter. This loss stems primarily from intensified transaction costs and other non-cash expenses related to inventory and asset adjustments post-merger.

Furthermore, Keenova's operational strategy includes navigating the complexities of the healthcare market, where pricing pressures and regulatory scrutiny are ever-present. The integration of Endo's assets continues to be an influential factor in overall performance, with Keenova keenly monitoring the evolving landscape.

Conclusion

Keenova Therapeutics stands at a crucial juncture as it moves forward in 2026. The first-quarter results reflect a combination of solid product performance and strategic foresight. As Keenova continues to expand its market presence and prepare for potential stock market listing in the latter half of the year, investors and industry stakeholders remain optimistic about its growth trajectory and ability to deliver on its mission of helping patients with unique and challenging health conditions.

For further updates on Keenova's performance and future initiatives, investors and consumers can visit the company's official website.